Polypeptide Attached To Or Complexed With The Agent (e.g., Protein, Antibody, Etc.) Patents (Class 424/9.34)
-
Patent number: 9386938Abstract: Diagnostic compositions and methods for imaging and/or assessing collagen are described. The diagnostic compositions can include collagen binding peptides.Type: GrantFiled: September 12, 2011Date of Patent: July 12, 2016Assignee: Collagen Medical, LLCInventors: Peter D. Caravan, Andrew Kolodziej, Zhaoda Zhang, Stephane Dumas, Biplab Kumar Das, Vincent Jacques, Richard Looby, Steffi K. Koerner, Wei-Chuan Sun, David R. Buckler, Aida Abujoub, Aaron K. Sato
-
Patent number: 9339539Abstract: The invention includes a magnetic nanoparticle molecular delivery vehicle to be used for transfection and delivery of therapeutic molecules across cell membranes and to specific sites in the body, using magnetic forces and ultrasound.Type: GrantFiled: April 5, 2012Date of Patent: May 17, 2016Assignee: Hidaca LimitedInventors: James Xing, Jie Chen
-
Patent number: 9289504Abstract: A protein nanocapsule having a single-protein core and a thin polymer shell anchored covalently to the protein core.Type: GrantFiled: March 9, 2010Date of Patent: March 22, 2016Assignee: The Regents of the University of CaliforniaInventors: Yunfeng Lu, Ming Yan, Juanjuan Du
-
Patent number: 9285449Abstract: Systems and methods for imaging and quantifying tissue magnetism with magnetic resonance imaging (MRI) are disclosed. According to an aspect, a method for MRI includes using an MRI system to acquire multiple image echoes of an object. The method also includes combining the image echoes. Further, the method includes generating an image of the object based on the combined image echoes for depicting a characteristic of the object.Type: GrantFiled: June 14, 2012Date of Patent: March 15, 2016Inventors: Chunlei Liu, Wei Li, Bing Wu
-
Patent number: 9150657Abstract: The present invention provides an antibody which recognizes an epitope recognized by an antibody produced by a hybridoma SH348-1 (FERM BP-10836) or a hybridoma SH357-1 (FERM BP-10837), an antibody produced by the hybridoma SH348-1 or the hybridoma SH357-1, an antibody obtained by humanizing the antibody produced by the hybridoma SH348-1 or the hybridoma SH357-1, a pharmaceutical agent comprising the antibody as an active ingredient, etc.Type: GrantFiled: May 22, 2013Date of Patent: October 6, 2015Assignee: Daiichi Sankyo Company, LimitedInventors: Jun Hasegawa, Toshiaki Ohtsuka, Atsushi Urano, Junko Yamaguchi, Toshinori Agatsuma, Kaori Nakahara, Takeshi Takizawa
-
Patent number: 9074980Abstract: The present invention relates to a method for the toxicity assessment of nano-materials, and more specifically, it is relates to an objective, reproducible and accurate assessment method for the unbiased toxicity testings of nano-materials, which minimize artifacts of the conventional methods for the toxicity assessment of the nano-materials by considering the dose characteristics of the nano-material itself using Selective multi-Plane Illumination Microcopy (SPIM); and the response characteristics of the nano-material using the improved or novel cellular responses assessment methods for nano-materials (e.g., modified MTT assay using image cytometric analysis, normal-inverted exposure apparatus, and modified flow cytometry), and a system and an apparatus thereof.Type: GrantFiled: October 21, 2011Date of Patent: July 7, 2015Assignee: INDUSTRY-UNIVERSITY CORPORATION FOUNDATION HANYANG UNIVERSITYInventors: Tae-Hyun Yoon, Song-Hee Lee, Dong-Wook Kwon, Jong-Hoon Park, Hyun-Ju Yoo, Hyun-Woo Nho
-
Patent number: 9073990Abstract: An isolated pore-forming polypeptide is disclosed which comprises a naturally-occurring plugging module and a naturally-occurring pore domain, wherein at least one amino acid of the pore-forming polypeptide is mutated to generate a protease cleavage site, serving to at least partially remove the plugging module from the pore domain. The pore forming polypeptides may be inserted into an encapsulating particle and positioned such that it is capable of forming a pore through the lipid layer of the particle in a presence of the protease.Type: GrantFiled: April 4, 2011Date of Patent: July 7, 2015Assignee: Bar-llan UniversityInventors: Yoav Paas, Ilya Pittel, Uri Nir, Barak Ben-David
-
Patent number: 9075907Abstract: A medical diagnosis assistance system comprising an image data storage part, a substance distribution information acquiring part, a display part; and a control part. The image data storage part is configured to store image data of a brain function image. The substance distribution information acquiring part is configured to detect the signal from within the brain of a subject and to acquire, based on the detected signal, substance distribution information indicating the distribution of the quantity of specified endogenous substances in each part of the brain. The control part is configured to control the display part to display the brain function image and the image information based on said acquired substance distribution information.Type: GrantFiled: January 30, 2008Date of Patent: July 7, 2015Assignees: Kabushiki Kaisha Toshiba, Toshiba Medical Systems CorporationInventor: Katsuhiko Fujimoto
-
Patent number: 9055919Abstract: A method includes concurrently modulating administration of at least two different contrast agents to a subject during an imaging procedure based on a modulation profile. The at least two different contrast agents exhibit different spectral characteristics. The method further includes performing a spectral decomposition of data indicative of the at least two different contrast agents, determining concentrations of the at least two different contrast agents based on the spectral reconstruction, and determining a perfusion parameter based on a ratio of the concentrations and the modulation profile.Type: GrantFiled: June 22, 2009Date of Patent: June 16, 2015Assignee: Koninklijke Philips N.V.Inventor: Roland Proksa
-
Publication number: 20150147278Abstract: The present invention provides a prophylactic or therapeutic agent for various malignant tumors, including currently intractable solid tumors, which contains a novel antibody having the ability to bind to human LAT1/CD98 and inducing antibody-dependent cellular cytotoxicity specifically against cancer cells as an active ingredient.Type: ApplicationFiled: December 5, 2014Publication date: May 28, 2015Applicants: Kinki University, Link Genomics, Inc.Inventors: Takashi Masuko, Shinichiro Niwa, Hidemi Hayashi, Dai Ogura, Takayuki Shindou
-
Patent number: 9034298Abstract: Described are amphiphilic polymers that are provided with chelating moieties. The amphiphilic polymers are block copolymers comprising a hydrophilic block and a hydrophobic block, with the chelating moieties linked to the end-group of the hydrophilic block. The disclosed polymers are capable of self-assembly into structures such as micelles and polymersomes. With suitable metals present in the form of coordination complexes with 5 the chelating moieties, the chelating amphiphilic polymers of the invention are suitable for use in various imaging techniques requiring metal labeling, such as MRI (T 1/T 2 weighted contrast agents or CEST contrast agents) SPECT, PET or Spectral CT.Type: GrantFiled: September 8, 2009Date of Patent: May 19, 2015Assignee: Koninklijke Philips N.V.Inventors: Holger Gruell, Anke De Vries, Sander Langereis, Johan Lub, Erica M. G. Aussems-Custers
-
Patent number: 9028801Abstract: The invention relates to a method of diagnosis of vCJD in a diagnostic sample of a valid body tissue taken from a human subject, which comprises detecting an increased concentration of a protein in the diagnostic sample, compared with a sample of a control human subject, the protein being: beta-actin (SwissProt Acc. No. P60709), apolipoprotein A-IV precursor (SwissProt Acc. No. P06727); haptoglobin beta-chain consisting of residues 162-406 (SwissProt Acc. No. P00738); haemoglobin beta chain (SwissProt Acc. No. P02023); or alpha-1-antitrypsin (SwissProt Acc. No. P01009); or a decreased concentration of a protein in the diagnostic sample, compared with a sample of a control, normal human subject, the protein being plasma protease (C1) inhibitor precursor (SwissProt Acc. No. P05155); complement component 1, s sub-component (SwissProt Acc. No. P09871); butyrylcholinesterase precursor (SwissProt Acc. No. P06276); complement component C4B (SwissProt Acc. No. P01028); lumican (SwissProt Acc. No.Type: GrantFiled: December 7, 2005Date of Patent: May 12, 2015Assignees: Electrophoretics Limited, Medical Research Council, University College LondonInventors: Malcolm Andrew Ward, John Collinge, Graham Stuart Jackson, Emma McGregor, Nicola Louise Leeds, James Campbell, Jules Arthur Westbrook, Helen Louise Byers
-
Publication number: 20150110721Abstract: A method for modulating a response signal includes introducing functionalized particles into a lumen of subsurface vasculature, wherein the functionalized particles are configured to interact with one or more target analytes present in blood circulating in the subsurface vasculature; and non-invasively detecting the one or more target analytes. A response signal, which may include a background signal and an analyte response signal related to interaction of the functionalized particles with the one or more target analytes, is transmitted from the subsurface vasculature. A modulation configured to alter the response signal such that the analyte response signal is affected differently than the background signal may be applied to a portion of subsurface vasculature. Analyte detection may be achieved by differentiating the analyte response signal from the background signal.Type: ApplicationFiled: October 23, 2013Publication date: April 23, 2015Applicant: Google Inc.Inventors: Andrew Conrad, Eric Peeters, Vikram Singh Bajaj, Jason Thompson, Mark Askew
-
Patent number: 8986655Abstract: PSMA ligands, compositions, and methods therefore are disclosed where the ligand is a peptide having the sequence X1X2CVEVX3QNSCX4X5 where X1-X5 are independently a natural or non-natural amino acid or a peptide having the sequence CALCEFLG [SEQ ID NO: 1]. Especially preferred aspects include diagnostic reagents for detection and/or quantification of PSMA in a sample, therapeutic reagents, and diagnostic imaging reagents.Type: GrantFiled: May 19, 2010Date of Patent: March 24, 2015Assignee: The Regents of the University of CaliforniaInventors: Gregory A. Weiss, Jessica Arter, Juan E. Diaz
-
Publication number: 20150071852Abstract: In one embodiment, an isolated antibody or functional fragment thereof which binds an antigenic peptide sequence of human FOXC1 is provided herein. Such antibodies or functional fragments may be used to diagnose, prognose or treat basal-like breast cancer. The antibody or functional fragment may be a monoclonal antibody produced by a hybridoma cell line. Thus, a hybridoma cell line that produces a FOXC1 monoclonal antibody which binds an antigenic peptide sequence of human FOXC1 as described above is also provided.Type: ApplicationFiled: April 10, 2014Publication date: March 12, 2015Applicant: John Wayne Cancer InstituteInventor: Xiaojiang Cui
-
Publication number: 20150071861Abstract: As a substance used as a contrast agent for a method of nuclear magnetic resonance analysis or a method of magnetic resonance imaging, a substance with high selectivity and high sensitivity was demanded. According to the present invention, when a polymer having, in a side chain thereof, a sequence of a 1H—13C—15N, 1H—15N—13C or 1H—13C—13C bond, that is, a structure labeled with stable isotopes of 13C and 15N, is used, the abundance of such a sequence in one molecule can be increased, and hence, high selectivity and higher sensitivity can be attained when used as a contrast agent.Type: ApplicationFiled: May 22, 2013Publication date: March 12, 2015Applicant: CANON KABUSHIKI KAISHAInventors: Teruyuki Kondo, Yasuhiro Aoyama, Hisatsugu Yamada, Yoshinori Hasegawa, Hidehito Tochio, Yu Kimura, Masahiro Shirakawa, Fuminori Sugihara, Tetsuya Matsuda, Shinsuke Sando, Masato Minami, Fumio Yamauchi, Tetsuya Yano, Hidetoshi Tsuzuki
-
Publication number: 20150056137Abstract: Provided is an activatable probe that undergoes intramolecular cyclization and subsequent aggregation in apoptotic tumor cells upon peptidase-initiated, and most advantageously caspase-3, activation. These caspase-sensitive nano-aggregation probes (C-SNAFs) are generally biocompatible, possess NIR spectral properties or may serve as PET or MRI imaging agents, and have a mechanism of target-mediated nanostructure self-assembly amenable to in vivo use. The probes encompass biocompatible condensation chemistry products that comprise D-cysteine and 2-cyano-6-hydroxyquinoline (CHQ) moieties linked to an amino-luciferin scaffold, and which can be activated by a two-step reaction requiring caspase-3/7-mediated cleavage of an aspartate-glutamate-valine-aspartate (L-DEVD) capping peptide and the free intracellular thiol-mediated reduction of the disulfide bond.Type: ApplicationFiled: August 20, 2014Publication date: February 26, 2015Inventors: Jianghong Rao, Deju Ye, Adam Shuhendler, Frederick Te-Ning Chin, Jongho Jeon, Bin Shen
-
Patent number: 8961949Abstract: The present invention provides a polymer-metal complex composite, which comprises a block copolymer capable of serving as a constituent member of a polymeric micelle and a metal complex having MRI contrast ability, accumulates in a tumor-specific manner, achieves high image contrast even in a small amount, and has reduced side effects and a long retention time in blood. The polymer-metal complex composite of the present invention comprises a block copolymer (A) represented by general formula (a) and a metal complex (B) having MRI contrast ability, wherein the composite comprises a structure in which a carboxyl anion of poly(carbo) in the copolymer (A) is attached to the metal complex (B) via a metal atom (M).Type: GrantFiled: June 26, 2009Date of Patent: February 24, 2015Assignee: Japan Science and Technology AgencyInventors: Kazunori Kataoka, Sachiko Kaida, Horacio Cabral, Michiaki Kumagai, Masaki Sekino
-
Publication number: 20150044135Abstract: The invention described herein relates to the detection, diagnosis, and treatment of intestinal metaplasias that develop to esophageal, gastric, and pancreatic adenocarcinoma. The stem cells and differentiated cells of these intestinal metaplasias show high expression of CDH17 as well as other proteins. The invention also includes a clonal population of Barrett's esophagus stem cells as well as the stem cells of the surrounding normal epithelia and methods of using them for the detection, diagnosis, and treatment of Barrett's esophagus.Type: ApplicationFiled: September 24, 2014Publication date: February 12, 2015Inventors: Wa Xian, Frank McKeon, Matthew Vincent, Khek Yu Ho
-
Patent number: 8945570Abstract: The invention described herein relates to novel nucleic acid sequences and their encoded proteins, referred to as 158P1D7 and variants thereof, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express 158P1D7 and variants thereof.Type: GrantFiled: October 26, 2012Date of Patent: February 3, 2015Assignee: Agensys, Inc.Inventors: Aya Jakobovits, Robert Kendall Morrison, Arthur B. Raitano, Pia M. Challita-Eid, Juan J. Perez-Villar, Karen Jane Meyrick Morrison, Mary Faris, Wangmao Ge, Jean Gudas, Steven B. Kanner
-
Patent number: 8940276Abstract: Provided are human alpha-synuclein-specific autoantibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for ?-synuclein are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for ?-synuclein targeted immunotherapy and diagnosis, respectively.Type: GrantFiled: December 21, 2009Date of Patent: January 27, 2015Assignees: Biogen Idec International Neuroscience GmbH, University of ZurichInventors: Andreas Weihofen, Jan Grimm, Roger Nitsch, Christoph Hock
-
Patent number: 8940272Abstract: Provided are novel human tau-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for tau are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for tau targeted immunotherapy and diagnosis, respectively.Type: GrantFiled: October 11, 2011Date of Patent: January 27, 2015Assignees: University of Zurich, Biogen Idec International Neuroscience GmbHInventors: Roger Nitsch, Feng Chen, Jan Grimm, Jean-Luc Baeriswyl, Christoph Hock
-
Publication number: 20140363377Abstract: The invention provides compositions and method for delivering a therapeutic or diagnostic agent to a disease site in a mammal, the method comprising administering to the mammal a therapeutically or diagnostically effective amount of a pharmaceutical composition, wherein the pharmaceutical composition comprises the therapeutic or diagnostic agent coupled to a Procaspase 8 polypeptide and a pharmaceutically acceptable carrier.Type: ApplicationFiled: June 18, 2014Publication date: December 11, 2014Inventor: Isabella TAI
-
Publication number: 20140363378Abstract: Disclosed are compositions that contain a plurality of biocompatible self-assembling molecules that transform from isolated molecules or spherical micelles in the circulation into cylindrical nanofibers in the acidic extracellular environment of tumors which can be used to achieve a higher relative concentration of imaging, drug delivery, or radiotherapeutic agents at the tumor site compared to non-tumor tissues. This transition is rapid and reversible, indicating the system is in thermodynamic equilibrium.Type: ApplicationFiled: February 1, 2013Publication date: December 11, 2014Inventors: Joshua E. Goldberger, Michael F. Tweedle
-
Patent number: 8901276Abstract: The present invention is directed to peptide reagents, methods for detecting colon pre-cancer (dysplasia with non-polypoid or polypoid morphology) or cancer using the peptide reagents, and methods for targeting pre-cancerous or cancerous colon cells using the peptide reagents.Type: GrantFiled: December 19, 2011Date of Patent: December 2, 2014Assignee: The Regents of the University of MichiganInventors: Thomas D. Wang, Sharon Miller, Bishnu Joshi
-
Patent number: 8877714Abstract: The present invention relates generally to receptor-selective variants of the low-density lipoprotein receptor-associated protein (RAP) and compositions thereof, methods of generating such variants and methods of using such receptor-selective RAP variant compositions for therapeutic purposes. The invention also relates to antibodies that bind to one or a small subset of CR-containing proteins.Type: GrantFiled: June 14, 2006Date of Patent: November 4, 2014Assignee: Raptor Pharmaceutical Inc.Inventors: Christopher M. Starr, Todd C. Zankel
-
Patent number: 8877158Abstract: It is an object of the present invention to provide a targeting agent that enables drug delivery to a neovascular site and the imaging of such a neovascular site, utilizing the effect of the agent to accumulate in the neovascular site. The present invention provides a targeting agent to a neovascular site, which comprises a gelatin-like protein.Type: GrantFiled: June 11, 2010Date of Patent: November 4, 2014Assignees: FUJIFILM Corporation, Kyoto UniversityInventors: Kentaro Nakamura, Yasuhiko Tabata
-
Publication number: 20140322132Abstract: Provided are fragments of human p97 (melanotransferrin) polypeptides having blood-brain barrier (BBB) transport activity, including variants and combinations thereof, conjugates comprising said p97 fragments, and related methods of use thereof, for instance, to facilitate delivery of therapeutic or diagnostic agents across the BBB.Type: ApplicationFiled: March 13, 2014Publication date: October 30, 2014Inventors: Timothy Z. Vitalis, Reinhard Gabathuler
-
Patent number: 8858939Abstract: The invention pertains to methods for treating ectopic pregnancy. More particularly, the present invention relates to methods for treating unruptured ectopic pregnancy using a non-surgical method comprising the administration of an EGFR inhibitor alone or in combination with an anti-metabolite e.g. methotrexate (MTX). The methodology is potentially applicable to treatment of unruptured ectopic pregnancies of all sizes.Type: GrantFiled: October 1, 2010Date of Patent: October 14, 2014Assignee: Monash UniversityInventors: Stephen Tong, Ulrika W. Nilsson, Terence Grant Johns
-
Publication number: 20140301945Abstract: Provided are novel human copper-zinc superoxide dismutase, also known as superoxide dismutase 1 or SOD1, specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for SOD1 are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for SOD1 targeted immunotherapy and diagnosis, respectively.Type: ApplicationFiled: December 19, 2011Publication date: October 9, 2014Applicants: UNIVERSITY OF ZURICH, NEURIMMUNE HOLDING AGInventors: Fabio Montrasio, Maria Grazia Barenco Montrasio, Jan Grimm, Roger Nitsch, Christoph Hock, Tobias Welt, Jordan McAfoose, Marcel Maier
-
Publication number: 20140286865Abstract: This invention relates, e.g., to a composition suitable for administration to the central nervous system (CNS), comprising a block copolypeptide hydrogel, which comprises a biologically active material that is mixed with the hydrogel or that is attached to the polypeptide chain of the hydrogel, wherein the composition is suitable for administration to the CNS. Also disclosed are methods of making and using compositions of the invention as depots or as scaffolds for cell migration, and pharmaceutical compositions and kits for implementing methods of the invention.Type: ApplicationFiled: February 18, 2014Publication date: September 25, 2014Applicant: The Regents of the University of CaliforniaInventors: Timothy J. Deming, Michael V. Sofroniew, Chu-Ya Yang, BingBing Song, Yan Ao
-
Patent number: 8834840Abstract: Compositions and/or mixtures comprising peptide amphiphile compounds comprising one or more contrast agents, as can be used in a range of magnetic resonance imaging applications.Type: GrantFiled: October 4, 2007Date of Patent: September 16, 2014Assignee: Northwestern UniversityInventors: Steve R. Bull, Thomas J. Meade, Samuel I. Stupp
-
Patent number: 8828681Abstract: The present invention is directed generally to eukaryotic cells comprising single-celled organisms that are introduced into the eukaryotic cell through human intervention and which transfer to daughter cells of the eukaryotic cell through at least five cell divisions, and methods of introducing such single-celled organisms into eukaryotic cells. The invention also provides methods of using such eukaryotic cells. The invention further provides single-celled organisms that introduce a phenotype to eukaryotic cells that is maintained in daughter cells. The invention additionally provides eukaryotic cells containing magnetotactic bacteria.Type: GrantFiled: March 15, 2013Date of Patent: September 9, 2014Assignee: Bell Biosystems, Inc.Inventors: Caleb B. Bell, III, Alexey Bazarov
-
Publication number: 20140241984Abstract: The invention describes antibodies having a high affinity for aggregated forms of ?-synuclein and a low affinity for monomeric forms of ?-synuclein. The antibodies are useful in the diagnosis of neurodegenerative diseases.Type: ApplicationFiled: December 23, 2013Publication date: August 28, 2014Applicant: UNITED ARAB EMIRATES UNIVERSITYInventor: OMAR EL-AGNAF
-
Publication number: 20140234214Abstract: The present disclosure provides methods of treating a tauopathy, involving administering an anti-Tau antibody. The present disclosure also provides anti-Tau antibodies, and formulations comprising same, for use in the methods.Type: ApplicationFiled: January 14, 2014Publication date: August 21, 2014Applicant: iPierian, Inc.Inventors: Irene Griswold-Prenner, Nancy E. Stagliano, Vu Dang
-
Publication number: 20140227179Abstract: Described herein are compositions and methods of use of anti-pancreatic cancer antibodies or fragments thereof, such as murine, chimeric, humanized or human PAM4 antibodies. The antibodies show novel and useful diagnostic characteristics, such as binding with high specificity to pancreatic and other cancers, but not to normal or benign pancreatic tissues and binding to a high percentage of early stage pancreatic cancers. Preferably, the antibodies bind to an epitope located within the second to fourth cysteine-rich domains of MUC5ac (amino acid residues 1575-2052) and are of use for the detection and diagnosis of early stage pancreatic cancer. In more preferred embodiments, the anti-pancreatic cancer antibodies can be used for immunoassay of serum samples, wherein the immunoassay detects a marker for early stage pancreatic cancer in serum. Most preferably, the serum is extracted with an organic phase, such as butanol, before immunoassay.Type: ApplicationFiled: April 1, 2014Publication date: August 14, 2014Applicant: IMMUNOMEDICS, INC.Inventors: Donglin Liu, David V. Gold, Chien-Hsing Chang, Serengulam V. Govindan, David M. Goldenberg
-
Publication number: 20140227175Abstract: The invention relates to Cathepsin-binding compounds bound to a carrier comprising a diagnostic moiety, for use in the diagnosis of inflammatory diseases, and/or for use in the diagnosis of neoplastic diseases, wherein the Cathepsin-binding compound binds to inflammatory cells of the tumour stroma. The invention also relates to Cathepsin B-targeting compounds and Cathepsin B-binding and liposome-binding compounds.Type: ApplicationFiled: June 22, 2012Publication date: August 14, 2014Applicant: J. Stefan InstituteInventors: Olga Vasiljeva, Georgy Mikhaylov, Boris Turk, Norbert Schaschke
-
Patent number: 8802057Abstract: A method of detecting target molecules comprising; conjugating a first magnetic particle to a first ligand to form a first magnetic particle ligand conjugate; adding the conjugate to a sample containing target molecules to form a mixture comprising, the free conjugate and conjugate-target molecule binding pairs; measuring a first magnetization of the mixture; subjecting the mixture to a first force; measuring a second magnetization value of the mixture; subtracting the second magnetization value from the first magnetization value to calculate a first force-induced magnetization contrast; subjecting the mixture to a second force; measuring a third magnetization of the mixture; and subtracting the third magnetization value from the second magnetization value to calculate a second force-induced magnetization contrast.Type: GrantFiled: July 21, 2011Date of Patent: August 12, 2014Assignee: University of Houston SystemInventors: Shoujun Xu, Li Yao
-
Patent number: 8785603Abstract: Provided herein are antigenic molecules that can be used to generate antibodies capable of binding to a vitamin D derivative, such as 25-hydroxyvitamin D2 and/or 25-hydroxyvitamin D3, or a 25-hydroxyvitamin D analog, such as a vitamin D-C22 immunogenic molecule or compound. Antibodies produced using these antigenic molecules, and related antigenic compounds, are also described. In addition, disclosed herein are methods for detecting vitamin D deficiency in a subject, methods for treating a subject suspected of having a vitamin D deficiency, methods for monitoring progression of vitamin D deficiency in a subject, and methods for monitoring treatment of vitamin D deficiency in a subject in need thereof. Also provided are methods and reagents for the detection or quantification of 25-hydroxyvitamin D2 and D3, methods for stabilizing vitamin D analogs, and methods for separating 25-hydroxyvitamin D2 and D3 from vitamin D binding protein in a biological sample.Type: GrantFiled: April 27, 2012Date of Patent: July 22, 2014Assignee: Siemens Healthcare Diagnostics Inc.Inventors: Niver Panosian Sahakian, Bruce A. Campbell, Spencer Hsiang-Hsi Lin, James Vincent Freeman, Qimu Liao, Ramon A. Evangelista
-
NANOPARTICLE COATED WITH LIGAND INTRODUCED WITH LONG HYDROPHOBIC CHAIN AND METHOD FOR PREPARING SAME
Publication number: 20140199235Abstract: The present invention relates to a nanoparticle having a linker connected to a long alkane or alkene chain, and a method for preparing the nanoparticle. The alkyl chain of C10-30 introduced with a ligand of the present invention can be coated on a hydrophobic nanoparticle through a noncovalent bond, enabling easy introduction of various ligands to the nanoparticle, and the nanoparticle having various functional groups prepared using the method can be applied to fluorescent detection, MRI, raman spectroscopy, optical detection, PET, SPECT, or gamma image device, and the ligand of the visualization agents can be modified to be used for new vessels detection, cancer cell detection, immunocyte detection, hepatocyte detection, cell death detection, and gene detection.Type: ApplicationFiled: January 31, 2012Publication date: July 17, 2014Applicant: SNU R&DB FOUNDATIONInventors: Jae Min Jeong, Young Kyoung Lee, Dong Soo Lee, June-Key Chung, Myung Chul Lee -
Patent number: 8771691Abstract: The present invention relates to methods for the treatment and the prognostic assessment of malignant pleural mesothelioma.Type: GrantFiled: December 14, 2009Date of Patent: July 8, 2014Assignee: Inserm (Institut National de la Sante et de la Recherche Medicale)Inventors: Patricia Forgez, Marco Alifano
-
Publication number: 20140178302Abstract: The present invention relates to a novel class of diagnostically or therapeutically effective compounds comprising novel aza-bicycloalkane based cyclic peptides, acting as a targeting moiety towards integrin receptors.Type: ApplicationFiled: January 13, 2014Publication date: June 26, 2014Applicant: BRACCO IMAGING S.P.A.Inventors: Luciano LATTUADA, Pierfrancesco Morosini, Fulvio Uggeri, Silvio Aime, Enzo Terreno, Daniela Delli Castelli, Carlo Scolastico, Leonardo Manzoni, Daniela Arosio
-
Patent number: 8758723Abstract: The present invention relates generally to the fields of chemistry and radionuclide imaging. More particularly, it concerns compositions, kits and methods for imaging and therapy involving N4 compounds and derivatives.Type: GrantFiled: April 19, 2007Date of Patent: June 24, 2014Assignee: The Board of Regents of the University of Texas SystemInventors: David J. Yang, Chang-Sok Oh, Dong-Fang Yu, Ali Azhdarinia, Saady Kohanim
-
Publication number: 20140154181Abstract: The invention provides RGD-containing cyclic peptidomimetics; conjugates of said peptidomimetics and a moiety of a payload selected from fluorescent probes, photosensitizers, chelating agents, or cytotoxic agents; and pharmaceutical compositions comprising these conjugates. The conjugates of the invention are useful both for diagnostic purposes and treatment of various diseases, disorders and conditions. More specifically, conjugates comprising fluorescent probes can be used for diagnostic purposes, e.g., visualization of organs and tissues, and diagnosis of tumors; conjugates comprising photosensitizers can be used for photodynamic therapy of both tumors and nonneoplastic tissues; conjugates comprising chelating agents can be used in radioimaging or radiotherapy; and conjugates comprising cytotoxic agents can be used for targeted chemotherapy.Type: ApplicationFiled: February 7, 2014Publication date: June 5, 2014Applicant: STEBA BIOTECH S.A.Inventors: Doron EREN, Tamar YECHEZKEL, Yoseph SALITRA, Natalia KOUDINOVA
-
Patent number: 8740872Abstract: The present disclosure describes a method for targeted delivery of permanently-acting or temporarily-acting neurotoxins, neurosuppressants, or other compounds having a neurologic effect to specific locations of the heart, including for example, but not limited to, nodes of the cardiac autonomic nervous system such as the atrial ganglionated plexi (GP). Chemical ablation of the atrial GP as described herein via magnetically-targeted magnetically-susceptible nanoparticles can effectively suppress GP activity and atrial fibrillation related, thereto without permanent damage to either myocardium or intrinsic CANS.Type: GrantFiled: October 19, 2010Date of Patent: June 3, 2014Assignee: The Board of Regents of the University of OklahomaInventors: Kenneth J. Dormer, Sunny S. Po, Benjamin J. Scherlag, Carey N. Pope
-
Publication number: 20140140933Abstract: The present disclosure provides antibodies that bind complement C1s protein; and nucleic acid molecules that encode such antibodies. The present disclosure also provides compositions comprising such antibodies, and methods to produce and use such antibodies, nucleic acid molecules, and compositions.Type: ApplicationFiled: November 1, 2013Publication date: May 22, 2014Inventors: Peter Van Vlasselaer, Graham Parry, Nancy E. Stagliano, Sandip Panicker
-
Publication number: 20140134103Abstract: Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils. Antibodies for inhibition of formation and/or increasing clearance of amyloid deposits in a patient thus effecting prophylaxis or treating amyloid disease.Type: ApplicationFiled: December 6, 2013Publication date: May 15, 2014Applicants: University of Tennessee Research Foundation, Elan Pharmaceuticals, Inc.Inventors: Dale B. SCHENK, Peter A. Seubert, Jonathan Wall, José Saldanha
-
Patent number: 8722019Abstract: The present invention is related to fragments of human melanotransferrin (p97). In particular, this invention relates to treatment of diseases through the introduction of the melanotransferrin fragment conjugated to a therapeutic or diagnostic agent to a subject.Type: GrantFiled: August 3, 2012Date of Patent: May 13, 2014Assignee: biOasis Technologies, Inc.Inventors: Wilfred Jefferies, Mei Mei Tian, Timothy Vitalis
-
Publication number: 20140112872Abstract: The present invention provides methods and apparatuses for detecting, measuring, or locating cells or substances present in even very low concentrations in vivo in subjects, using targeted magnetic nanoparticles and special magnetic systems. The magnetic systems can comprise magnetizing subsystems and sensors subsystems, including as examples SQUID sensors and atomic magnetometers. The magnetic systems can detect, measure, or location particles bound by antibodies to cells or substances of predetermined types. Example magnetic systems are capable of detecting sub-nanogram amounts of these nanoparticles.Type: ApplicationFiled: October 18, 2013Publication date: April 24, 2014Inventors: Edward R Flynn, Victor Gerald Grafe, Steven C. Miller
-
Publication number: 20140105827Abstract: The present invention relates to biomarkers for colon cancers, specifically adenomas and adenocarcinomas in the GI tract. The inventors have discovered that the expression and/or overexpression of biomarkers such as CLDN1, GPR56, GRM8, LY6G6D, TLR4 and SLCO1B3 are indicative of adenomas and adenocarcinomas. A method of detecting colon cancer using targeted molecular imaging agents is also presented.Type: ApplicationFiled: September 30, 2013Publication date: April 17, 2014Applicant: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.Inventors: David L. Morse, Robert J. Gillies